Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
7.59
+0.07 (0.93%)
At close: Feb 21, 2025, 4:00 PM
7.70
+0.11 (1.45%)
After-hours: Feb 21, 2025, 7:57 PM EST
Nuvectis Pharma Employees
Nuvectis Pharma had 13 employees as of December 31, 2023. The number of employees increased by 2 or 18.18% compared to the previous year.
Employees
13
Change (1Y)
2
Growth (1Y)
18.18%
Revenue / Employee
n/a
Profits / Employee
-$1,490,308
Market Cap
181.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 13 | 2 | 18.18% |
| Dec 31, 2022 | 11 | 3 | 37.50% |
| Dec 31, 2021 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
NVCT News
- 16 days ago - Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option - GlobeNewsWire
- 16 days ago - Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback - Seeking Alpha
- 17 days ago - Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock - GlobeNewsWire
- 18 days ago - Nuvectis Pharma Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug - Benzinga
- 3 months ago - Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 4 months ago - PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - Business Wire
- 6 months ago - Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers - GlobeNewsWire